TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06192654

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Small intestinal submucosa (SIS) graft urethroplasty
Description: Standard technique of doing a substitution urethroplasty with no modification to the surgical steps. Instead of an autologous oral bucal mucosa graft, the small intestinal submucosa graft is sutured to the healty urethral area after incision of the urethra at the stricture location.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous oral bucal mucosa graft urethroplasty
Description: Standard technique of doing a substitution urethroplasty with no modification to the surgical steps. The autologous oral bucal mucosa graft is sutured to the healty urethral area after incision of the urethra at the stricture location.
Study: NCT05914090

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS
Description: Among adults, patients undergoing elective extracorporeal circulation for cardiac surgery are included in the ERAS strategy intervention plan, which mainly includes preoperative education, preoperative oral intake of multidimensional carbohydrate beverages, multimodal analgesia, blood protection strategies, correction of perioperative hypoalbuminemia, early removal of tracheal intubation, maintenance of blood sugar at reasonable levels, and targeted liquid therapy.
Study: NCT05727345

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene brachial plexus block
Description: Preoperative ultrasound-guided interscalene brachial plexus block application

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shoulder anterior capsular block
Description: Preoperative ultrasound-guided shoulder anterior capsular(SHAC) block application
Study: NCT06524297

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metaverse system (Patients)
Description: The experimental group will undergo preoperative training using the metaverse surgical simulation system for 15 minutes before selecting the surgical incision site (this refers to residents receiving the assisted training). The trial process requires participants' consent to provide high-resolution CT images as the basis for reconstructing digital twin organs. Except for the intervention training, the surgery, postoperative care, follow-up, and other treatment processes the participants receive will be the same as those for typical patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metaverse system (Resident Physician)
Description: The participants (residents) will receive 15 minutes of preoperative training using the Metaverse surgical simulation system. They will superimpose the digital twin model onto the patient on the operating table and use the CT cross-sectional matching function within the Metaverse system to locate the lesion. The participants (residents) can use the system to repeatedly simulate incision sites and mark planned entry points on the patient by overlaying the virtual model onto the real patient. Except for the intervention training with the system, the subsequent surgery, postoperative care, follow-up, and other treatment processes the patients receive will be the same as usual.
Study: NCT05922878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALTO-300
Description: ALTO-300 capsule QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule QD
Study: NCT05731583

Intervention type: DEVICE
Intervention: Home pulse oximetry monitoring
Description: A digital application and a wireless oximeter were provided to both groups. Oxygen saturation, heart rate and (optional) body temperature were monitored at least twice a day.

Intervention type: DEVICE
Intervention: Home pulse oximetry monitoring
Description: A digital application and a wireless oximeter were provided to both groups. Oxygen saturation, heart rate and (optional) body temperature were monitored at least twice a day.
Study: NCT05256628

Intervention type: OTHER
Group type: OTHER
Intervention: Early Weightbearing
Description: Patients randomized to undergo this study intervention will bear weight, as tolerated, on the affected side straight after surgery, with crutches for additional support and stability. They will be allowed to stop using crutches in the weeks after surgery as they feel more comfortable and stable on their surgical leg.
Study: NCT06210711

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Description: Standard clinical treatment received by all patients admitted to BUMC, BSWMC Temple or FH/MCW trauma centers. At BUMC and FH/MCW, this may include an evaluation by a licensed psychologist or psychiatrist and continued follow-up psychotherapy and/or medication as needed. At BSWMC Temple this may include an evaluation by a licensed psychiatrist and follow up treatment as needed. In all locations this therapy does not consist of trauma-focused therapy and will be summarized in the analysis as a part of standard of care.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Prolonged Exposure Therapy
Description: Brief PE will include 3 therapy sessions, each lasting approximately 60 minutes. The treatment is manualized and has been successfully implemented and evaluated in other challenging environments (i.e., Emergency Department. Trauma center). Brief PE includes education about common reactions to trauma, breathing retraining, prolonged (repeated) imaginal exposure to trauma memories, repeated in vivo/behavioral exposure to situations that participants are avoiding due to trauma-related fear, and discussion of thoughts and feelings related to exposure exercises. This discussion addresses patients' unrealistic beliefs about themselves and the world. In addition, patients are given homework to complete between each session (breathing practice, listening to the session recording, and completing behavioral exposures).
Study: NCT06078241

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous lidocaine infusion
Description: Intravenous lidocaine infusion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block (ESPB)
Description: Unilateral erector spinae plane block

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous infusion of normal saline
Description: Intravenous infusion of normal saline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ESPB with normal saline
Description: Unilateral ESPB with normal saline
Study: NCT06550934

Intervention type: PROCEDURE
Intervention: Fracture stabilization
Description: isolated posterior surgical fracture stabilization vs. combined anterior-posterior surgical fracture stabilization

Intervention type: PROCEDURE
Intervention: Fracture stabilization
Description: isolated posterior surgical fracture stabilization vs. combined anterior-posterior surgical fracture stabilization
Study: NCT06305182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metreleptin
Description: Metreleptin 3 mg is packaged in 3 ml Type I glass vials with chlorobutyl rubber stoppers, and aluminum seals with plastic flip-off caps. The vials are stored in refrigerator (2 - 8°C) and protected from light. Metreleptin for injection is a sterile, white, solid lyophilised cake.~Prior to patient use, the content of a vial is reconstituted with 0.6 ml of water for injection for a final formulation of 10 millimolar (mM) glutamic acid, 2% glycine, 1% sucrose, 0.01% polysorbate 20, potential hydrogen (pH) 4.25. The resulting solution is administered by subcutaneous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: The placebo will consist of sterile 0.9% saline (Sodium chloride), drawn up from a 10 ml i.v. vials. The placebo will be administered as an subcutaneous injection in an identical procedure as the metreleptin verum.
Study: NCT05708196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alloplast bone grafting material (EthOss, Ethoss Regeneration Ltd, Silsden, UK).
Description: After tooth extraction, the tooth socket will begrafted with Alloplast grafting material

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allograft bone grafting material.
Description: After tooth extraction, the tooth socket will be grafted with allograft grafting material
Study: NCT05231954

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive Digital Marker for screening for ADRD
Description: Patients in the primary care clinics randomized to PDM+QDRS will have Electronic Health Record Data of their patients run through the PDM, a machine learning algorithm which can predict ADRD one year and three years prior to its onset. In addition, patients from these clinics will have their patients complete the QDRS, a validated patient reported outcome (PRO) tool. This combined approach will assess the value of early detection of ADRD and if the annual well visit can overcome the barriers related to early detection of ADRD.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive Digital Marker for screening for ADRD
Description: Patients in the primary care clinics randomized to PDM+QDRS will have Electronic Health Record Data of their patients run through the PDM, a machine learning algorithm which can predict ADRD one year and three years prior to its onset. In addition, patients from these clinics will have their patients complete the QDRS, a validated patient reported outcome (PRO) tool. This combined approach will assess the value of early detection of ADRD and if the annual well visit can overcome the barriers related to early detection of ADRD.
Study: NCT05328609

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Semaine Hormonal Imbalance & The Daily
Description: All participants will undergo a menstrual cycle without intervention to establish a baseline, and then will be given the intervention (dietary supplement) for a second menstrual cycle.
Study: NCT05632159

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mg sulphate
Description: Induction of anesthesia will be done by injecting fentanyl 2 μg/kg, propofol1.5-2.5 mg/kg and atracurium 0.5 mg/kg for muscle relaxation. With extra administration of intraoperative Magnesium sulphate 30 mg /kg as loading dose over 10 min then 10 mg /kg/ has maintenance dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: conventional anaesthesia
Description: Induction of anesthesia will be done by injecting fentanyl 2 μg/kg, propofol1.5-2.5 mg/kg and atracurium 0.5 mg/kg for muscle relaxation.
Study: NCT06036745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab + SOX
Description: Pembrolizumab 200mg, ivdrip, q3w; Oxaliplatin 135mg/m2, ivdrip，q3w; Trastuzumab 40 mg/m2，po bid，d1\~d14，q21d. Each cycle consists of three weeks, totaling eight cycles
Study: NCT05260736

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infraclavicular brachial plexus block
Description: Named after the anatomical site; patients will be applied infraclavicular brachial plexus block with costoclavicular lateral, costoclavicular medial or lateral sagittal approach.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infraclavicular brachial plexus block
Description: Named after the anatomical site; patients will be applied infraclavicular brachial plexus block with costoclavicular lateral, costoclavicular medial or lateral sagittal approach.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infraclavicular brachial plexus block
Description: Named after the anatomical site; patients will be applied infraclavicular brachial plexus block with costoclavicular lateral, costoclavicular medial or lateral sagittal approach.
Study: NCT04675931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAE609
Description: Two doses of Intravenous Cipargamin will be evaluated in the initial phase of the study (Cohorts 1-2).~These doses will cover a wider exposure range and facilitate the selection of an appropriate dose for later Cohorts 3-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAE609
Description: Two doses of Intravenous Cipargamin will be evaluated in the initial phase of the study (Cohorts 1-2).~These doses will cover a wider exposure range and facilitate the selection of an appropriate dose for later Cohorts 3-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAE609
Description: Two doses of Intravenous Cipargamin will be evaluated in the initial phase of the study (Cohorts 1-2).~These doses will cover a wider exposure range and facilitate the selection of an appropriate dose for later Cohorts 3-5.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Artesunate
Description: Parenteral artesunate is the WHO recommended first line treatment for severe malaria. Hence IV artesunate is used as comparator. Also, this will be used as rescue medication for participants where IV KAE609 is not working.

Intervention type: DRUG
Group type: OTHER
Intervention: Coartem
Description: Oral Standard of Care
Study: NCT04607668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Description: Trilaciclib diluted in dextrose 5% in water or normal saline (sodium chloride solution 0.9%) administered by IV infusion over approximately 30 (±10) minutes no more than 4 hours prior to each Day 1 chemotherapy administration. Second dose of trilaciclib was administered on Day 2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dextrose 5% in water or normal saline (sodium chloride solution 0.9%) administered by IV infusion over 30 (±10) minutes no more than 4 hours prior to each Day 1 chemotherapy administration. Second dose of placebo was administered on Day 2.
Study: NCT06335329

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Discussion of point-of-care ultrasound lung findings
Description: The investigator will obtain point-of-care ultrasound images to assess the lung findings in 12 lung fields. These 12 lung fields will include the standard protocol of the upper and lower halves of the anterior, lateral, and posterior chest bilaterally. Subjects' ultrasound images will be scored using a modified lung ultrasound score (LUS). Each of the 12 lung fields will be scored from 0-5, with a total score of 0-60 (noted below). The participants will watch their ultrasound being performed, looking at their lungs in real time. Then, the ultrasound findings will be discussed with the participant.~Modified LUS 0: No B-lines present~1. 1 well-defined B-line~2. 2-3 well-defined B-lines~3. \>3 B-lines~4. Confluent B-lines~5. Lobar consolidation~   * C: Noted if subpleural consolidation present~  * E: Noted if pleural effusion present
Study: NCT05903794

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EXG102-031
Description: EXG102-031 is a recombinant adeno-associated virus (rAAV) expressing an angiopoietin domain and VEGF receptor (ABD-VEGFR) fusion protein. EXG102-031 will be administered by subretinal injecting into one eye of each participant.
Study: NCT03987035

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BeGraft Peripheral (BGP) Stent Graft System as bridging stent
Description: BGP Stent Graft System as bridging stent
Study: NCT06051201

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ReceptIVFity test (vaginal microbiome swab)
Description: A vaginal self-swab for determination of the vaginal microbiome is performed by the patient.~For women of European origin randomization in one of the following groups:~SDM group: Using Shared-Decision-Making according to the ReceptIVFity microbiome profile with its predicted chance of achieving a pregnancy in the current cycle.~Physician decision group: Postponing treatment until a switch to a favorable ReceptIVFity microbiome profile
Study: NCT05256628

Intervention type: OTHER
Group type: OTHER
Intervention: Protected Weightbearing
Description: Patients randomized to undergo this study intervention will be instructed to be touch weightbearing for 6 weeks after surgery. They will use crutches and put no more weight on the surgical side than what it takes to crack an egg. After the 6-week mark, they will be able to bear weight.
Study: NCT05186233

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phototherapy
Description: Light exposure recommendations provided by SHIFT mobile application

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phototherapy
Description: Light exposure recommendations provided by SHIFT mobile application
Study: NCT06051305

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Training
Description: Participants will use gamified sensory training technology once daily for 8 weeks. This will involve participants completing a 15 minute sensory training session using the provided technology. The tool used in this study has two components. The first is a game that can be downloaded onto any smartphone device. The second component is two tactile devices that can be attached to the body.
Study: NCT05866952

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed Tomography of the Chest
Description: Quantitative Computed Tomography of the chest in the inspiratory and expiratory phases will be performed to assess regional lung ventilation as well as pulmonary vascular volume and distribution

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed Tomography of the Chest
Description: Quantitative Computed Tomography of the chest in the inspiratory and expiratory phases will be performed to assess regional lung ventilation as well as pulmonary vascular volume and distribution

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed Tomography of the Chest
Description: Quantitative Computed Tomography of the chest in the inspiratory and expiratory phases will be performed to assess regional lung ventilation as well as pulmonary vascular volume and distribution
Study: NCT06108232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-99282
Description: Given by PO
Study: NCT05953389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitolisant
Description: histamine H3 receptor antagonist/inverse agonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo of pitolisant tablets
Study: NCT06100887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevasemten Dose 1
Description: Sevasemten is administered orally once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevasemten Dose 2
Description: Sevasemten is administered orally once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevasemten Dose 3
Description: Sevasemten is administered orally once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is administered orally once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is administered orally once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is administered orally once per day
Study: NCT05720143

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osseodensification
Description: Procedure: the horizontal and vertical osteotomy will make by Piezo and bone splitting will do by osseodensification bur. After that Immediate implantation will be done.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic mallet
Description: Procedure: the horizontal and vertical osteotomy will do by Piezo and bone splitting will make by chisels of magnetic mallet. Immediate implantation will be done after splitting.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezo-surgery
Description: Procedure: the horizontal and vertical osteotomy will do by Piezo and bone splitting will make by inserts of piezosurgery and bone expander. Finally, immediate implantation will be placed.
Study: NCT05236816

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fatigue (physical exercise)
Description: Subjects were evaluated before and after a fatiguing exercise of hip abductor muscles that consisted to repeat hip abduction with rate and range of motion until a target decrease of force is attempt
Study: NCT06039579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280
Description: VH4004280 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280
Description: VH4004280 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280
Description: VH4004280 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4011499
Description: VH4011499 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4011499
Description: VH4011499 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4011499
Description: VH4011499 will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VH4004280 Matching Placebo
Description: VH4004280 matching placebo will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VH4004280 Matching Placebo
Description: VH4004280 matching placebo will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VH4011499 Matching Placebo
Description: VH4011499 matching placebo will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VH4011499 Matching Placebo
Description: VH4011499 matching placebo will be administered.
Study: NCT05561920

Intervention type: DEVICE
Intervention: High - speed video endoscopy (HSV)
Description: Describe anatomical and morphological characteristics o phonatory movement of PEM in laryngectomy patients

Intervention type: DEVICE
Intervention: Acoustic voice analysis
Description: acoustic program (lingWAVES - Voice and speech analyser) - measuring the values of acoustic parameters in voice recordings

Intervention type: BEHAVIORAL
Intervention: Quality of life questionnaire
Description: Filling out questionnaires
Study: NCT06271512

Intervention type: OTHER
Intervention: No Intervention
Description: This is non-interventional study.
Study: NCT05789537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SerpinPC
Description: Administered as SC injection.
Study: NCT06311864

Intervention type: DRUG
Intervention: Daridorexant 50 mg
Description: As indicated by the physician
Study: NCT06359158

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital stethoscope use
Description: In this interventional study, 84 medical students were randomly allocated to an intervention group utilizing a novel digital stethoscope curriculum or a control group receiving traditional instruction. The intervention leveraged digital stethoscopes, enabling visualization and analysis of recorded breath sounds. Pre- and post-assessments evaluated respiratory
Study: NCT02403505

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CEA protein antigen plus BCG Vaccine Mix for percutaneous use
Description: * By the percutaneous route with the multiple puncture device~* CEA protein antigen 0.05 mg plus BCG Organism 50 MG Mix